The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Will Be Presenting Riluzole Prodrugs to Treat ALS and Melanoma, Funded by a Phase II SBIR Grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA

 

Doylestown, PA. September 8, 2014- FCCDC will be presenting Riluzole Prodrugs to treat ALS and melanoma, funded by a Phase II SBIR grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA (http://sbir.cancer.gov/investorforum/presenters.asp).